The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Chugai Renews Record Earnings in 2018 on New Drugs, Exports
Chugai Pharmaceutical delivered record sales and operating profit in 2018 as drug price cuts in April were more than offset by strong sales of new drugs including Hemlibra (emicizumab) and Tecentriq (atezolizumab) and exports to Roche, with one-off gains from…
To read the full story
Related Article
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
October 25, 2018
- Chugai Sees Solid Uptake for Tecentriq, Hemlibra but CEO Frets Pricing Stability
July 27, 2018
- Chugai Notches Up Record Earnings in 2017 on Bullish Exports, Milestones
February 2, 2018
BUSINESS
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
- Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…